AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31069459
Drug: Probiotic yoghurt
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic yoghurt (100 g/day from 24 weeks of gestation until delivery)
Trial: 21194827
Drug: Hyoscine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine (10 mg)
Trial: 16446007
Drug: Propionyl l-carnitine
RxNorm normalized name: glycine propionyl-L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionyl l-carnitine (PLC) 2 g/day
Trial: 12522753
Drug: Investigational antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational antiretroviral agents
Trial: 25089881
Drug: Dimension cues
RxNorm normalized name: DIMENSION
DrugBank: Dithiopyr (DB15230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimension cues indicating the relevant stimulus dimension (e.g., 'number')
Trial: 25089881
Drug: Mapping cues
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mapping cues providing information regarding both the relevant task identity and its category-to-key mapping (e.g., 'one three')
Trial: 25089881
Drug: Neutral Stroop
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral Stroop condition (name color patches, low control demand)
Trial: 20105610
Drug: Initial nonoperative
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial nonoperative management (intravenous antibiotics with percutaneous drainage followed by interval laparoscopic appendectomy)
Trial: 17284750
Drug: Watercress supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watercress supplementation (85 g raw watercress daily for 8 weeks)
Trial: 11972998
Drug: Dextromethorphan 100
RxNorm normalized name: guaifenesin/dextromethorphan 100 mg-10 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 100 mg
Trial: 10442377
Drug: UFT (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (300 to 400 mg/day for 2 years)
Trial: 10442377
Drug: UFT (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (600 mg/day)
Trial: 10442377
Drug: UFT (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (300 mg/day)
Trial: 2207297
Drug: Recainam (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recainam (oral doses 54-208 mg kg-1 in mice)
Trial: 2207297
Drug: Recainam (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recainam (oral doses 25-110 mg kg-1 in rats)
Trial: 2207297
Drug: Recainam (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recainam (oral doses 50-100 mg kg-1 in rabbits)
Trial: 2207297
Drug: Recainam (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recainam (i.v. doses 1-15 mg kg-1 in rhesus monkeys)
Trial: 2207297
Drug: Recainam (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recainam (oral doses 6-60 mg kg-1 in dogs)
Trial: 2207297
Drug: Recainam (400-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recainam (400-800 mg in humans)
Trial: 2207297
Drug: Recainam (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recainam (single or multiple doses in dogs)
Trial: 2207297
Drug: Recainam (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recainam (i.v. doses in rats and rabbits)
Trial: 2207297
Drug: Recainam (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recainam (i.v. doses in dogs, rhesus monkeys, and humans)
Trial: 30900152
Drug: Topically-administered haemocoagulase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically-administered haemocoagulase (batroxobin)
Trial: 27837415
Drug: Sexual intercourse
RxNorm normalized name: Zinc Gluconate 50 mg ORAL CAPSULE [Pegasus Male Sexual Enhancer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sexual intercourse 3-4 times/week with symptomatic treatment
Trial: 27837415
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment only (control group)
Trial: 25885280
Drug: 35 mg
RxNorm normalized name: papain 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg risedronate orally, once a week for 6 months postoperatively
Trial: 23313145
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for prescription opioid dependence
Trial: 9925129
Drug: Ergocalciferol supplement
RxNorm normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ergocalciferol supplement providing 14 microg/d
Trial: 27265880
Drug: Mirabegron (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron (50 mg per day) for 8 weeks
Trial: 27265880
Drug: Imidafenacin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidafenacin (0.2 mg per day) for 8 weeks
Trial: 24980414
Drug: Circumcision plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circumcision plus antibiotic, anti-inflammatory, and α-blocker therapy
Trial: 24980414
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (medications only, no circumcision)
Trial: 19235739
Drug: Olfactory training
RxNorm normalized name: BOS TAURUS OLFACTORY BULB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olfactory training (12 weeks, twice daily exposure to four odors: phenyl ethyl alcohol, eucalyptol, citronellal, eugenol)
Trial: 17008974
Drug: Orbofiban (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orbofiban (oral glycoprotein IIb/IIIa inhibitor)
Trial: 10761167
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg PO QD for 10 days
Trial: 6364909
Drug: Chenodiol, 375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodiol, 375 mg/d
Trial: 30678674
Drug: Problem-solving cognitive
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving cognitive behaviour therapy (PSCBT) plus treatment as usual (TAU)
Trial: 30052729
Drug: Avelumab 10mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avelumab 10mg/kg by intravenous infusion every 2 weeks
Trial: 30052729
Drug: Physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice of chemotherapy (paclitaxel 80mg/m2 on days 1, 8, and 15 or irinotecan 150mg/m2 on days 1 and 15)
Trial: 23627026
Drug: Kurarinol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kurarinol (600 mg intravenous drip once a day for one month, followed by 200 mg oral capsule three times a day)
Trial: 23627026
Drug: Silybin meglumine
RxNorm normalized name: silybin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silybin meglumine tablet (same dosage as treatment group)
Trial: 17870226
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose levels in quartile I (QI) 100 mg/dl
Trial: 17870226
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose levels in quartile II (QII) 130 mg/dl
Trial: 17870226
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose levels in quartile III (QIII) 162 mg/dl
Trial: 17870226
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose levels in quartile I (QI) 100 mg/dl after adjustment for confounders
Trial: 17870226
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose levels in quartile II (QII) 130 mg/dl after adjustment for confounders
Trial: 17870226
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose levels in quartile III (QIII) 162 mg/dl after adjustment for confounders
Trial: 12458653
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg + HCTZ 12.5 mg
Trial: 12458653
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg + HCTZ 25 mg
Trial: 12458653
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg + other antihypertensive +/- HCTZ (12.5 or 25 mg)
Trial: 8724536
Drug: 5-day intravenous
RxNorm normalized name: ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-day intravenous infusions of 2-CdA
Trial: 8724536
Drug: intermittent 2-hour
RxNorm normalized name: CATHETER,INTERMITTENT 14FR H #94144
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intermittent 2-hour infusions of 2-CdA
Trial: 8724536
Drug: continuous 24-hour
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous 24-hour infusion of 2-CdA
Trial: 1770128
Drug: Intranasal buserelin
RxNorm normalized name: buserelin
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal buserelin 200 micrograms four hourly for 21 days
Trial: 1770128
Drug: Subcutaneous buserelin
RxNorm normalized name: buserelin
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous buserelin 500 micrograms twice a day for 7 days, followed by 500 micrograms daily for 14 days
Trial: 1770128
Drug: Subcutaneous buserelin
RxNorm normalized name: buserelin
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous buserelin 500 micrograms three times a day for 7 days
Trial: 6761186
Drug: Aspirin 330
RxNorm normalized name: aspirin 330 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 330 mg + Dipyridamole 75 mg three times daily
Trial: 29796934
Drug: Allogenic bone
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogenic bone marrow-derived mesenchymal stromal cells (BM-MSCs) by intrathecal infusion (1×10^6 cells/kg body weight, four infusions once a week)
Trial: 28973311
Drug: Stereotactic radiosurgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic radiosurgery (SRS) with bevacizumab, prescribed dose escalated from 18 to 22 Gy, single dose of bevacizumab given prior to SRS and continued until progression.
Trial: 17071161
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (once-weekly, 45-minute stretching sessions)
Trial: 11823389
Drug: Continued antidepressants
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued antidepressants before surgery (Group A, n=40)
Trial: 11823389
Drug: Discontinued antidepressants
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinued antidepressants 72 hr before surgery (Group B, n=40)
Trial: 1971991
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) (3.4 g/d)
Trial: 1971991
Drug: Linoleic acid
RxNorm normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linoleic acid (14.3 g/d)
Trial: 1971991
Drug: Alpha-linolenic acid
RxNorm normalized name: Alpha-linolenic Acid
DrugBank: alpha-Linolenic acid (DB00132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-linolenic acid (9.2 g/d)
Trial: 375690
Drug: Zinc sulfate,
RxNorm normalized name: Zinc sulfate, anhydrous
DrugBank: Zinc sulfate (DB09322)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc sulfate, 0.2 g three times daily
Trial: 28675897
Drug: Self-monitoring of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-monitoring of daily lifestyle
Trial: 19686525
Drug: Slow-release oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release oral morphine (SROM) and Methadone
Trial: 8627437
Drug: Investigational pneumococcal
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational pneumococcal conjugate vaccine
Trial: 8627437
Drug: Licensed pneumococcal
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed pneumococcal polysaccharide vaccine (given as a booster)
Trial: 8627437
Drug: Licensed pneumococcal
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed pneumococcal polysaccharide vaccine (given as a primary injection to control group)
Trial: 6324710
Drug: Cimetidine (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1,200 mg/day orally)
Trial: 6324710
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg/day orally)
Trial: 6324710
Drug: Warfarin sodium
RxNorm normalized name: Warfarin Sodium
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin sodium (1.5 mg/kg)
Trial: 22782416
Drug: Fluorouracil plus
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil plus folinic acid (20 mg/m2 of folinic acid via IV bolus followed by 425 mg/m2 of fluorouracil via IV bolus, administered 1 to 5 days every 28 days)
Trial: 22782416
Drug: Gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1000 mg/m2 IV infusion once a week for 3 of every 4 weeks for 6 months)
Trial: 16829196
Drug: Oral cryotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cryotherapy (holding ice cubes in the oral cavity before, during, and after 5FU infusion)
Trial: 22967016
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no oral cryotherapy)
Trial: 2368892
Drug: Lignocaine 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 2% with adrenaline 1:200,000 plus normal saline 0.01 ml/kg
Trial: 25776532
Drug: Early, goal-directed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early, goal-directed therapy (EGDT) - a 6-hour resuscitation protocol
Trial: 21853765
Drug: Traditional pharmacotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional pharmacotherapy (Fluoxetine 20 mg)
Trial: 11336164
Drug: IL‐1beta (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐1beta (10 ng/ml)
Trial: 11336164
Drug: ALLN (proteasome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALLN (proteasome and NF‐kappaB activation inhibitor)
Trial: 30581161
Drug: Prophylactic entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic entecavir (ETV) before chemotherapy and at least 6 months after completion of chemotherapy
Trial: 23150919
Drug: Bendamustine 90
RxNorm normalized name: bendamustine 90 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine 90 mg/m² plus Bortezomib 1.0 mg/m²
Trial: 23150919
Drug: Bendamustine 50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine 50, 70, or 90 mg/m² plus Bortezomib 1.0 mg/m²
Trial: 21214899
Drug: Exhale® Drug‐Eluting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exhale® Drug‐Eluting Stent
Trial: 18957146
Drug: Lung recruitment
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung recruitment maneuvers (RMs) performed twice daily for 3 days, starting at 35 cm H(2)O for 20 seconds, with potential increases to 40 cm H(2)O and 45 cm H(2)O or longer durations (30 seconds, then 40 seconds) if needed.
Trial: 16581613
Drug: Antioxidants (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidants (combination tablet of vitamins A, C, and E)
Trial: 8624267
Drug: 5-fluorouracil 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil 500 mg m‐2, epidoxorubicin 120 mg m‐2, cyclophosphamide 500 mg m‐2 (FE120C) administered at 21 day intervals without haematopoietic growth factors
Trial: 1361718
Drug: Beta-adrenergic blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenergic blocker treatment
Trial: 1676594
Drug: Atracurium 0.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.45 mg kg‐1
Trial: 27387971
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl (2 μg/kg; maximum, 100 μg)
Trial: 27387971
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (0.1 mg/kg; maximum, 8 mg)
Trial: 29652460
Drug: Computer-controlled injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-controlled injection system
Trial: 25899007
Drug: OBE001 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBE001 600 mg/day
Trial: 25899007
Drug: Betamethasone 12
RxNorm normalized name: Betamethasone 120 microgram/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone 12 mg/day
Trial: 25899007
Drug: OBE001 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBE001 and Betamethasone combination
Trial: 21904204
Drug: Peginterferon α‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon α‐2a (40 KD) 180 µg/week plus ribavirin (800 mg/day) for 24 weeks
Trial: 21904204
Drug: Peginterferon α‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon α‐2a (40 KD) 180 µg/week plus ribavirin (1000/1200 mg/day) for 48 weeks
Trial: 21904204
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with peginterferon α‐2a (40 KD) plus ribavirin
Trial: 17220050
Drug: Clopidogrel (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (single oral dose) under fed condition (after a standardized high fat breakfast)
Trial: 17220050
Drug: Clopidogrel (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (single oral dose) under fasted condition
Trial: 17220050
Drug: Clopidogrel (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (single oral dose) under fed condition
Trial: 9088811
Drug: Esmolol 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 4.0 mg kg‐1
Trial: 1768544
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate 40 mg kg‐1
Trial: 9088811
Drug: Lignocaine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 1.5 mg kg‐1
Trial: 7515193
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 10(6) KIU aprotinin (1 x 10(6) as a loading dose before cardiopulmonary bypass, 1 x 10(6) in the priming volume and 2.5 x 10(5)/hour intraoperatively)
Trial: 7515193
Drug: Aprotinin (reduced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (reduced dosage)
Trial: 29737802
Drug: Cinnamon (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon (3 capsules of 500 mg each daily for 8 weeks)
Trial: 25346054
Drug: Placebo session
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo session (deceptive instructions regarding administration of an analgesic drug)
Trial: 15685254
Drug: Tamoxifen ('Nolvadex')
RxNorm normalized name: tamoxifen Oral Tablet [Nolvadex]
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen ('Nolvadex') 20 mg/day
Trial: 15685254
Drug: Anastrozole ('Arimidex')
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole ('Arimidex') 1 mg/day
Trial: 9433653
Drug: Grepafloxacin 400
RxNorm normalized name: grepafloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grepafloxacin 400 mg, daily for 7 days
Trial: 3803106
Drug: Urecholine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urecholine (oral or subcutaneous)
Trial: 12920411
Drug: Mirtazapine (30‐45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (30‐45 mg/d)
Trial: 12920411
Drug: Sertraline (50‐150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50‐150 mg/d)
Trial: 12920411
Drug: Mirtazapine and
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine and Sertraline
Trial: 10843485
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (HRT) with non-conjugated estrogens, mean duration of HRT was 25 months, starting on average 18 months after completed therapy for ovarian cancer.
Trial: 7509399
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1:100,000 adrenaline and 5% ethanolamine injection
Trial: 26341547
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 200 μg beclomethasone dipropionate (BDP) in standard posture